This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

23 Nov 2011

Pfizer to Acquire Excaliard Pharmaceuticals

Pfizer has signed an agreement to acquire privately owned biopharmaceutical company Excaliard Pharmaceuticals.

Pfizer Inc. and Excaliard Pharmaceuticals, Inc. announced yesterday a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.


Pfizer will provide to Excaliard an upfront payment and contingent payments if certain milestones are achieved. The acquisition is expected to close before the end of the year.


"The acquisition of Excaliard is part of our corporate research and development strategy to actively complement our robust internal project pipeline with innovative and differentiated drugs from biotech partners," said Mikael Dolsten, pr

Related News